, ANR-10-IAIHU-06. This work was partially funded by the Program Hospitalier de Recherche Clinique FTLD-exome (to ILB., promotion Assistance PubliqueeHôpitaux de Paris) and by the ANR-PRTS PREV-DEMALS project (to ILB
Philippe Couratier, Frédéric Blanc (Hôpitaux Civils, Strasbourg), Claire Bouteleau-Bretonnière ,
Marie Chupin (CATI, ICM, Paris), Olivier Colliot, Stéphane Lehéricy (Hôpital Pitié-Salpêtrière Salpêtrière ,
Factors influencing the age at onset in familial frontotemporal lobar dementia: important weight of genetics, French Clinical and Genetic Research Network on FTD/FTD-ALS, Predict-PGRN & PrevDemAls Study Groups, 2017. ,
Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population, Am. J. Hum. Genet, vol.92, pp.345-353, 2013. ,
Current insights into the C9orf72 repeat expansion diseases of the FTLD/ ALS spectrum, Trends Neurosci, vol.36, pp.450-459, 2013. ,
, GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS, vol.72, pp.245-256, 2011.
Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia, Hum. Mol. Genet, vol.23, pp.749-754, 2014. ,
RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention, Neuron, vol.80, pp.415-428, 2013. ,
The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter, Mol. Psychiatry, vol.21, 2016. ,
, Neuron, vol.90, pp.535-550, 2016.
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration, Proc. Natl. Acad. Sci. U. S. A, vol.110, pp.4530-4539, 2013. ,
C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing, J. Alzheimers Dis, vol.34, pp.485-499, 2013.,
URL : https://hal.archives-ouvertes.fr/hal-00924796
, Lancet Neurol, vol.11, pp.323-330, 2012.
Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD, Hum. Mol. Genet, vol.24, pp.3133-3142, 2015. ,
, , pp.257-268, 2011.
Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifier, Acta Neuropathol. (Berl.), vol.129, pp.39-52, 2015. ,
Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration, Acta Neuropathol. (Berl.), vol.130, pp.978-988, 2013. ,
Clinical evidence of disease anticipation in families segregating a C9orf72 repeat expansion, JAMA Neurol, vol.74, pp.445-452, 2017. ,
Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion, Am. J. Hum. Genet, vol.92, pp.981-989, 2013. ,